News & Trends - Pharmaceuticals
Sanofi and GSK initiate clinical trial of vaccine candidate
Pharma News: Sanofi and GSK initiated the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.
The Phase 1/2 clinical trial is a randomised, double blind and placebo-controlled trial designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of the COVID-19 vaccine candidate. A total of 440 healthy adults are being enrolled in the trial across 11 investigational sites in the United States.
The companies anticipate first results early December 2020 which will support the initiation of a Phase 3 trial in December 2020. If data are sufficient for licensure application, the plan is to request regulatory approval in the first half of 2021.
Sanofi is leading the clinical development and registration of the COVID-19 vaccine. Preclinical data showed an acceptable reactogenicity profile and data based on two injections of the adjuvanted recombinant vaccine showed high levels of neutralizing antibodies that are comparable to levels in humans who recovered from the COVID-19 infection. Pre-clinical results will be published later this year. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021.
“Sanofi and GSK bring proven science and technology to the fight against the global COVID-19 pandemic, with the shared objective of delivering a safe and effective vaccine,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. “The initiation of our clinical study is an important step and brings us closer to a potential vaccine which could help defeat COVID-19. Our dedicated teams and partner continue to work around the clock as we aim to deliver the first results in early December. Positive data will enable a prompt start of the pivotal phase 3 trial by the end of this year.”
Roger Connor, President of GSK Vaccines added, “Moving this vaccine candidate into clinical development is an important moment in the progress towards addressing the global pandemic we are all facing. This builds on the confidence shown by governments already in the potential of this protein-based adjuvanted vaccine candidate, which utilizes established technology from both companies, and can be produced at scale by two of the leading vaccine manufacturers globally. We now look forward to the data from the study, and if positive, beginning Phase 3 by the end of the year.”
News & Trends - MedTech & Diagnostics
Roche Diagnostics MD bids farewell after two-decades, leading the organisation to new heights of success
Diagnostics & MedTech News: The Managing Director of Roche Diagnostics Australia, Allison Rossiter, has announced her resignation, effective September 2024. […]
MoreNews & Trends - Pharmaceuticals
Is Australia ready to play a leading role in precision nuclear medicines?
Pharma News: A newly released discussion paper unveils Australia’s preparedness to take the helm in the rise of the global […]
MoreNews & Trends - MedTech & Diagnostics
Minimally invasive procedure a first in epilepsy treatment
MedTech & Diagnostics News: An Australian-first procedure utilising MRI-guided, minimally invasive surgery has been introduced for the treatment of epilepsy […]
MoreNews & Trends - Pharmaceuticals
Stakeholders unite in international call to tackle breast cancer gaps and inequities
Pharma News: Breast Cancer Network Australia (BCNA) has united in an international call to raise breast cancer care standards and […]
More